After publication of this article [1], concerns were raised about similarity with a closely related article by the same authors in the Chinese Journal of Practical Surgery [2] which was not discussed in the above publication.

The Corresponding author (KW) and first author (QC) responded to the concern, stating that the results presented in [2] are from preliminary experiments investigating the effects of 0.5g/L or 1.0g/L trastuzumab and 15nmol/L fulvestrant on human HR+/HER2+ breast cancer cell line BT-474 for 48h, including effects on cell proliferation, cell apoptosis, and the expression levels of proteins p-Akt and p-MAPK, whereas the PLOS ONE article [1] presents the results of follow-up experiments, which investigated the effects of 0.13mg/ml trastuzumab and 34nmol/L fulvestrant on a BT-474 cell line, and of 0.65mg/ml trastuzumab and 45nmol/L fulvestrant on a ZR-75-1 cell line, both for 72h. Furthermore, in the follow-up experiments presented in [1], the authors also studied these effects in mouse tumor xenografts.

Additionally, in contrast to the Data Availability statement in [1], all relevant data were not provided within the article and its Supporting Information files. With this Correction, the authors provide the original raw data in S1–S2 Files and via Dryad: https://doi.org/10.5061/dryad.7mp37.

The Data Availability statement is updated to: All relevant data are within the paper, its Supporting Information files, and via Dryad: https://doi.org/10.5061/dryad.7mp37.

A member of the PLOS ONE Editorial Board reviewed the concerns and was satisfied that the two articles [1, 2] are sufficiently distinct from one another to warrant separate publications despite their similar design.